Citadel Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-13,300
| Closed | -$9K | – | 9301 |
|
|
2017
Q4 | $9K | Sell |
13,300
-7,500
| -36% | -$3.79K | ﹤0.01% | 7900 |
|
|
2017
Q3 | $7K | Sell |
20,800
-16,400
| -44% | -$5.75K | ﹤0.01% | 7452 |
|
|
2017
Q2 | $17K | Sell |
37,200
-1,300
| -3% | -$944 | ﹤0.01% | 7329 |
|
|
2017
Q1 | $46K | Buy |
38,500
+12,500
| +48% | +$15.6K | ﹤0.01% | 7063 |
|
|
2016
Q4 | $34K | Buy |
26,000
+6,100
| +31% | +$10.6K | ﹤0.01% | 6968 |
|
|
2016
Q3 | $42K | Sell |
19,900
-1,800
| -8% | -$3.56K | ﹤0.01% | 6889 |
|
|
2016
Q2 | $35K | Buy |
+21,700
| New | +$41.6K | ﹤0.01% | 6490 |
|
|
2016
Q1 | – | Sell |
-14,700
| Closed | -$18K | – | 9365 |
|
|
2015
Q4 | $18K | Sell |
14,700
-3,300
| -18% | -$10.6K | ﹤0.01% | 8035 |
|
|
2015
Q3 | $134K | Buy |
18,000
+4,900
| +37% | +$37.5K | ﹤0.01% | 6654 |
|
|
2015
Q2 | $94K | Buy |
13,100
+1,100
| +9% | +$8.57K | ﹤0.01% | 7143 |
|
|
2015
Q1 | $103K | Buy |
12,000
+3,000
| +33% | +$26.8K | ﹤0.01% | 6826 |
|
|
2014
Q4 | $90K | Sell |
9,000
-40,300
| -82% | -$344K | ﹤0.01% | 6739 |
|
|
2014
Q3 | $488K | Buy |
49,300
+35,300
| +252% | +$523K | ﹤0.01% | 4652 |
|
|
2014
Q2 | $242K | Sell |
14,000
-3,000
| -18% | -$48.9K | ﹤0.01% | 5349 |
|
|
2014
Q1 | $302K | Sell |
17,000
-7,400
| -30% | -$143K | ﹤0.01% | 5015 |
|
|
2013
Q4 | $447K | Sell |
24,400
-8,200
| -25% | -$155K | ﹤0.01% | 4156 |
|
|
2013
Q3 | $874K | Sell |
32,600
-5,600
| -15% | -$120K | ﹤0.01% | 3245 |
|
|
2013
Q2 | $705K | Buy |
+38,200
| New | +$675K | ﹤0.01% | 3507 |
|
Citadel Advisors's RPRX Position: Q1 2018 in Review
Citadel Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 15,518 shares — an estimated $10K sold.
Citadel Advisors first reported a position in RPRX in Q2 2013 and held it in 11 quarters. The position peaked at $35.8M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Citadel Advisors reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Citadel Advisors sold 15,518 Repros Therapeutics Inc. shares in Q1 2018, an estimated $10K.
- Citadel Advisors first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 11 quarters.
- Citadel Advisors's Repros Therapeutics Inc. position peaked at $35.8M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.